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Bart Klijs1, Suzie J Otto1*, Robert J Heine2, Yolanda van der Graaf3, Jan J Lous4 and Harry J de Koning1Abstract
Background: We describe the design and present the results of the first year of a population-based study of
screening for type 2 diabetes in individuals at high risk of developing the disease. High risk is defined as having
abdominal obesity.
Methods: Between 2006 and 2007, 79,142 inhabitants of two Dutch municipalities aged 40–74 years were
approached to participate in screening. Eligible participants had a self-reported waist circumference of ≥80 cm for
women and ≥94 cm for men, and no known pre-existing diabetes. Of the respondents (n = 20,578; response rate
26%), 16,135 were abdominally obese. In total, 10,609 individuals gave written informed consent for participation
and were randomized into either the screening (n = 5305) or the control arm (n = 5304). Participants in the
screening arm were invited to have their fasting plasma glucose (FPG) measured and were referred to their general
practitioner (GP) if it was ≥6.1 mmol/L. In addition, blood lipids were determined in the screening arm, because
abdominal obesity is often associated with cardiovascular risk factors. Participants in both arms received written
healthy lifestyle information. Between-group differences were analyzed with Chi-square tests and logistic regression
(categorical variables) and unpaired t-tests (continuous variables).
Results: The screening attendance rate was 84.1%. Attending screening was associated with age at randomization
(OR = 1.03, 95% CI 1.02-1.04), being married (OR = 1.57, 95% CI 1.33-1.83) and not-smoking currently (OR = 0.52,
95% CI 0.44-0.62). Of the individuals screened, 5.6% had hyperglycemia, and a further 11.6% had an estimated
absolute cardiovascular disease risk of 5% or higher, according to the Systematic Coronary Risk Evaluation risk
model. These participants were referred to their GP.
Conclusions: Self-reported home-assessed waist circumference could feasibly detect persons at high risk of
hyperglycemia or cardiovascular disease. Continuation of the large-scale RCT is warranted to test the hypothesis
that targeted population-based screening for type 2 diabetes leads to a significant reduction in cardiovascular
morbidity and mortality.
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Type 2 diabetes is a major public health problem affecting
more than 285 million people worldwide [1]. Diabetes is
not only associated with an increased risk of developing
microvascular complications [2], but also with a high risk
of cardiovascular [3] and all-cause mortality [4]. Because
of these complications, diabetes imposes a significant bur-
den on the quality of life of the patient and on the health
care system, and reduces the number of healthy life years.
Diabetes prevention is, therefore, a major concern, and
both diabetes and public health organizations worldwide
have expressed the need for diabetes screening in asymp-
tomatic individuals [5–10].
Type 2 diabetes meets many of the criteria for screening
which were formulated by Wilson & Jungner [11] to aid
the decision regarding whether or not to introduce a
population-based screening program. Type 2 diabetes is
an important health problem that can be diagnosed by
means of simple, non-invasive and acceptable screening
tests [12,13]. The onset of the disease is estimated to
occur 9–12 years before clinical diagnosis [14]. Effective
treatment options, either lifestyle modifications or medical
treatment, are available for asymptomatic individuals [15].
Recently, the multicenter Anglo-Danish-Dutch Study of
Intensive Treatment in People with Screen Detected
Diabetes in Primary Care (ADDITION-Europe) demon-
strated that early intensive management of screen-detected
type 2 diabetes was associated with a non-significant rela-
tive reduction in the incidence of cardiovascular events
after 5-years of follow-up compared with the screen-
detected type 2 diabetes cases receiving usual care [13,16].
However, the effectiveness of screening as a means of pre-
vention of diabetes has not yet been established [6,9,10].
Resulting from the epidemic growth of overweight,
obesity and abdominal obesity, the number of newly diag-
nosed type 2 diabetes cases is expected to grow sharply in
the coming years (439 million in 2030, [1]), which consti-
tutes a further threat to public health [1,17]. Waist cir-
cumference has been put forward as first-step screening
tool for the identification of undiagnosed diabetes, be-
cause there is strong evidence that this anthropometric
measure gives better prediction of incident diabetes
than body mass index (BMI) [18–21].
The current population-based randomized controlled
trial (RCT) was set up to (a) assess the performance of
waist circumference measurement as a first-step screen-
ing tool to identify individuals at high risk of developing
diabetes; (b) examine the effectiveness of type 2 diabetes
screening; and (3) ascertain whether early detection and
treatment of type 2 diabetes results in a reduction
and/or prevention of related morbidity and mortality
compared with not offering screening. This paper
describes the design and feasibility of this population-
based RCT.Methods
Study population
Participants were recruited among the inhabitants (males
and females aged 40–74 years) of the working area of two
Municipal Health Services in the Southwest Region of the
Netherlands. Their name and address information was
obtained from municipal authority records. An invitation
letter together with the study material, comprising of an
information brochure, a consent form, a tape meas-
ure and a questionnaire were sent by mail to the tar-
get population. The questionnaire contained questions on
demographic features such as marital status and education,
self-perceived health, weight and height, lifestyle, symptoms
and diabetes related risk factors, family history of diabetes
and personal history of selected diseases, including cardio-
vascular diseases, stroke, and diabetes.
The individuals were requested to measure their waist
circumference twice with the tape measure sent to their
home addresses and fill out their measurements on the
questionnaire, in addition to data on sociodemographic
characteristics, lifestyle and risk factors. After com-
pletion of the questionnaire, the potential participants
returned it in the enclosed postage-free reply envelope.
Eligibility, which was based on the absence of pre-existing
diabetes and a self-reported waist circumference indicating
abdominal obesity, was ascertained upon receipt of the
questionnaires. Abdominal obesity was defined as a waist
circumference of ≥80 cm for women and ≥94 cm for
men, following the cut-off points of the International
Diabetes Federation [8].
The validity of the self-reported waist circumference
was assessed in a subset of 160 persons by comparing
the self-measurements with measurements taken by a
trained nurse. The Cohen's kappa, which was calculated
as a proxy for the reliability between self-reported and
professionally-measured waist circumference, was an
acceptable 0.64.
A flowchart of the study is presented in Figure 1.
The study protocol and materials were approved by the
Medical Ethical Review Committee of Erasmus MC and
the RCT was registered with Current Controlled Trials
(ISRCTN75983009).Randomization
Eligible consenting respondents were stratified by gender
and individually randomized at a 1:1 ratio to the inter-
vention (screening) arm or the control arm using a ran-
dom number generator. Participants in the screening
arm received an invitation to attend screening, which
consisted of fasting plasma glucose (FPG) measurement
and information about the importance of a healthy life-
style (Netherlands Nutrition Centre). Those in the con-
trol arm only received the healthy lifestyle information.
Screening armControl arm
Follow-up outcome measurement
Source population
Respondents
Eligible
Figure 1 Flowchart of the screening trial.
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FPG was used as the screening criterion in accordance
with the Dutch College of General Practitioners’ guide-
lines [22]. The FPG cut-off values were 7.0 mmol/L or
higher for diabetes and between 6.1 and 6.9 mmol/L for
Impaired Fasting Glucose (IFG) [22]. As dyslipidemia
are often present in overweight and obese subjects, and
it is clinical practice to measure blood lipids in patients
with diabetes, we opted to additionally measure serum
lipids (total cholesterol, high-density lipoprotein, HDL,
cholesterol and triglycerides). FPG concentrations were
determined using the hexokinase method. Fasting serum
total cholesterol, HDL cholesterol and triglycerides were
quantified using an enzymatic colorimetric method.
All analyses were performed on the Beckman AU2700
chemical analyzer (Beckman Coulter Nederland BV,
Woerden, Netherlands), using kits supplied by Beckman.
Low-density lipoprotein (LDL) was calculated using the
Friedewald formula [23].
Individuals with a FPG level of 7.0 mmol/L or higher
were referred to their general practitioners (GP) for con-
firmatory diagnostic testing and treatment, which included
glycemic control by lifestyle intervention or antihyperglyce-
mic medication (oral agents and eventually insulin if neces-
sary), and management of any present cardiovascular risk
factors. Individuals with IFG were also referred to their GP
for FPG monitoring and treatment of possible cardiovascu-
lar risk factors according to the GP guidelines. Participants
were told their blood glucose level; this informationwas also given to their GP. Normoglycemic individuals
with an estimated absolute cardiovascular disease risk of
5% or higher, according to the Systematic Coronary Risk
Evaluation (SCORE) risk model, were also referred to their
GP [24]. The SCORE risk estimates are calculated based
on age, blood pressure level, current smoking status and
the ratio of total cholesterol to HDL cholesterol.
Because all participants in this RCT received the same
disease information, those assigned to the control arm
might take opportunistic testing after learning about the
simplicity of the screening test. Therefore, FPG testing
in the control arm was monitored through their GPs
and linkages with laboratory databases, similar to a pre-
vious prostate cancer screening trial [25].Outcome measures
The primary endpoint of the trial was the first occur-
rence of a fatal or non-fatal cardiovascular event within
the follow-up period after randomization. A cardiovascu-
lar event was defined as non-fatal coronary heart disease,
non-fatal stroke or death from any disease of the circula-
tory system (among diabetic cases and those at intermedi-
ate to high cardiovascular risk). Estimates of prevented
microvascular complications are also important, but this
study primarily focuses on macrovascular complications,
because these are by far the most important contributor
to premature death among patients with diabetes. A sec-
ondary analysis will include the primary non-fatal
endpoint, as well as non-cardiovascular diabetes-related
morbidity and mortality, all-cause mortality and cardio-
vascular interventions (e.g. revascularization).
Intermediate endpoints include the prevalence/incidence
of IFG and newly screen-detected type 2 diabetes, screening
performance (attendance, referral and detection rates, and
test characteristics), number of individuals with an absolute
cardiovascular disease risk of 5% or higher (intermediate to
high), and temporal changes in the levels of blood para-
meters (glucose, HbA1c, lipids and blood pressure).Follow-up and data collection
For each participant, a minimum follow-up period of 10
years is planned. During follow-up, information on the
time of diabetes diagnosis, cardiovascular risk profiles,
cardiovascular morbidity, diabetic complications and
use of medication will be obtained from GPs and from the
National Hospital Discharge Register. Data on cardiovas-
cular risk profiles, cardiovascular morbidity and medi-
cation use will also be collected for those referred to
their GP based on their absolute cardiovascular dis-
ease risk. Vital status will be ascertained through rec-
ord linkage with the Cause of Death Registry of
Statistics Netherlands.
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In the sample size calculations we estimated the mini-
mum number of participants required to identify a sta-
tistically significant 20% reduction in non-fatal and fatal
cardiovascular events in the screening compared with
the control arm. The expected rate of the composite
outcome of cardiovascular events in an aging cohort of
40–74 years at entry was estimated at 2% per year, based
on 2003 age and gender specific data obtained from the
Hospital Admission Registry for non-fatal events and
Statistics Netherlands for fatal events. Using age-specific
abdominal obesity prevalence data, the number of events
was estimated in the sub-population with abdominal
obesity [26]. Using the method developed by Baan and
coworkers [27] to assess the diabetes-related mortality in
the Dutch population, we additionally accounted for the
prevalence of pre-existing diabetes among individuals
with abdominal obesity [6], the relative risk of develop-
ing type 2 diabetes in this group [26], and sex-specific
hazard rates for cardiovascular events. We estimated
that the required number of participants per study arm
over 10 years was 30,885 to show a reduction of 20%,
with a power of 80% and a two-sided significance level
of 5%, assuming a contamination rate of 10% in the con-
trol arm, as previously reported for prostate-specific
antigen screening [25].
Feasibility phase
In the first year of the trial, we examined the feasibility
of home-assessed and self-reported waist circumference
measurements as a first-step screening tool for recruit-
ing individuals at high risk. The sociodemographic char-
acteristics of the respondents and the intermediate
endpoints, particularly attendance and detection rate
were assessed. Socioeconomic status was based on 2006
social status ranking of the Social and Cultural Planning
Office. The ranking, from 1 (high status) to 3965 (low
status) is estimated based on income, employment status
and level of education in the households within postal
code areas.
In 2006 and 2007, 79,142 inhabitants of the Dutch
municipalities of Capelle aan den IJssel and Dordrecht,
in the age group 40–74 years were invited to participate.
The mailings were sent out in two different ways. Half
of the population received the complete study material,
consisting of a letter of invitation, information brochure,
tape measure and consent form (one-step screening ap-
proach). The other half first received a letter of invita-
tion containing a brief introduction to the study, an
explanation of how to measure their waist size, and a
tape measure. Individuals who responded and who were
judged potentially eligible were then sent an accompany-
ing letter, information brochure and the consent form
(two-step screening approach). We aimed to find outwhich method produced the greatest response from
people at high risk, and what the costs of each strategy
were. In either approach strategy, those eligible for par-
ticipation were randomized only if they gave their
informed consent.
Statistical analysis
Differences between respondents and non-respondents and
between the control arm and the screening arm were com-
pared using Chi-square tests for categorical variables and
unpaired t-tests for continuous variables.
To examine the effect of the variables age, waist size
(continuous) and gender, marital status, education, smok-
ing status, family history and country of birth (categorical)
on the odds of attending screening, univariate logistic re-
gression was used and then a multivariate model was con-
structed with the variables that had a univariate p-value
of ≤0.10. The results are presented as odds ratio (OR)
and corresponding 95% confidence interval (CI).
All analyses were performed using SPSS version 17
(SPSS, Chicago, IL, USA). A p-value of <0.05 was con-
sidered statistically significant.
Results
A total of 20,578 of the 79,142 individuals approached in
the municipalities of Capelle aan den IJssel and Dordrecht
returned the questionnaire (26% response rate). The
sociodemographic characteristics of the respondents and
non-respondents are presented in Table 1. Compared with
the non-responders, the responders in both munici-
palities were older, predominantly females and born in the
Netherlands. In both municipalities there was a tendency
of higher response rates among those of middle to high
social status. The overall response among people born in
the Netherlands was 27.8%, and among immigrants was
15.3%. Of the major ethnic groups, the lowest response
was among people born in Morocco (7.8%), compared
with those born in Turkey (12.7%), the Dutch Antilles
(16.4%) and Surinam (19.8%).
Assuming a prevalence of 27.5% [26], 21,764 out of
79,142 individuals approached for participation were
expected to have abdominal obesity. In total, 10,609
individuals, which is 48.7% of the expected abdominally
obese population, were eligible and randomized as part
of the trial (Figure 2). The one-step screening strategy,
i.e. asking consent for participation before ascertain-
ment of eligibility, yielded a slightly higher proportion
of participants than the two-step strategy. Consequently,
the costs of recruitment per participant were lower for the
one-step approach than for the two-step approach: the
costs were €5.90 and €4.60 (USD 7.55 and 5.89) per par-
ticipant in the screening and the control arm in the one-
step procedure, and €6.67 and €5.43 (USD 8.58 and 6.98),
in the two-step procedure.
Table 1 Comparison between respondent and non-respondent to initial questionnaire in the two municipalities
Capelle aan den IJssel Dordrecht
Total Responders Non-responders P-value* Total Responders Non-responders P-value*
N=29,163 n= 7,779 n= 21,385 N=49,979 N=12,799 N=37,180
Age at mailing, median, yrs† 53.6 55.1 52.9 0.000 54.1 55.9 53.5 0.000
Gender, male, % 47.9 45.9 48.6 0.000 49.6 46.5 50.7 0.000
Country of birth, %
Netherlands 82.9 88.3 80.9 0.000 84.0 89.9 81.9 0.000
Other 17.1 11.7 19.1 16.0 10.1 18.1
Western country 6.6 4.7 7.2 6.3 4.8 6.8
Non-Western country 10.6 7.0 11.8 9.7 5.3 11.2
Social Status, %
High 30.3 39.2 27.0 0.000 0.8 0.6 0.9 0.000
Middle high 5.1 3.8 5.6 43.1 51.3 40.3
Middle low 42.8 33.2 46.4 23.6 21.7 24.3
Low 21.8 23.8 21.0 32.5 26.4 34.6
*Chi-square test for comparison of proportions and unpaired t-test for comparison of continuous variables between responders and non-responders.
†Age at mailing of study material.
Klijs et al. BMC Public Health 2012, 12:671 Page 6 of 11
http://www.biomedcentral.com/1471-2458/12/671The characteristics of the participants randomized in
the screening (n= 5305) and in the control arm (n= 5304)
are presented in Table 2. Among those in the screening
arm invited for FPG measurement, 4457 participants actu-
ally attended screening (84.1% attendance rate). Screening
attendance was significantly related to age at randomization
(OR=1.03, 95% CI 1.02-1.04, p<0.001), being married
(OR=1.69, 95% CI 1.44-1.97, p < 0.001), not-smoking cur-
rently (OR=0.47, 95% CI 0.40-0.56, p < 0.001) and born in
the Netherlands (OR=1.34, 95% CI 1.05-1.70, p = 0.017).
In the multivariate analysis, only country of birth was no
longer statistically significant.
In total, 251 persons were found to have glucose
levels ≥6.1 mmol/L at screening (5.6%), which prompted a
referral to their GP. The distributions of the IFG and dia-
betes detection rates across males and females according
to their waist circumference are presented in Figure 3.
Based on their lipids, 518 screened participants (11.6%) had
a moderate to high cardiovascular risk (SCORE risk ≥5%)
and were referred to their GP.
Discussion
The availability of effective treatment options and the
fact that screening can advance the moment of diagnosis
logically lead to the suggestion that systematic screening
for type 2 diabetes will reduce cardiovascular-related
morbidity and mortality. However, an RCT is required
to confirm this hypothesis and assess whether screening
is cost-effective. The aim of our extensive feasibility as-
sessment was to examine the performance of home-
assessed and self-reported waist circumference measure-
ments as first-step screening tools for recruiting high-risk
individuals. Self-reported waist circumference proved tobe a feasible method for detecting persons at risk of IFG,
type 2 diabetes and/or high cardiovascular risk. Given the
percentage of newly diagnosed diabetes by waist circum-
ference, a cut-off value of ≥94 cm could be used for males,
and of ≥88 cm could be used for females. Because the
one-step strategy, whereby consent for participation was
asked before proven eligibility, yielded slightly more high-
risk persons than the two-step strategy, while saving the
costs of an extra mailing, the one-step strategy is the pre-
ferred recruitment method.
The feasibility of using abdominal obesity to detect
persons with unknown diabetes or at high cardiovascular
risk has previously been assessed in different settings
[28–30]. Van den Donk et al. [29] reported a 27.5% de-
tection rate for metabolic syndrome in 1721 indivi-
duals who were abdominally obese. In a validation study,
Korhonen et al. [30] showed that 95% of all new cases of
diabetes and 84% of all new cases of IFG could be identi-
fied based on the presence of abdominal obesity. Although
specificity could not be assessed in our study, in line with
the aforementioned studies, we found self-reported home-
assessed abdominal obesity to be a feasible tool for detect-
ing persons with unknown diabetes and/or who were at
high cardiovascular risk.
In the Netherlands, diabetes screening has previously
been examined in at least two studies. In the ADDITION
Netherlands study (2002–2004), population-based screen-
ing was performed via GPs [31]. Of all 56,978 persons
who were invited to participate based on the Symptom
Risk Questionnaire (SRQ), 17,883 (30%) were screened.
The SRQ contains questions on age, sex, BMI, family his-
tory of diabetes, frequent thirst, use of antihyperten-
sive medication, shortness of breath, claudication, and
Response 32.6% 
N= 12 954
Response 19.3% 
N= 7 624
Abdominal obese 
N= 10 109
Abdominal obese 
N= 6 026
two-step screening approach 
N= 39 724
one-step screening approach 
N=39 418
Eligible 
N= 9 504
Eligible 
N= 5 670
Informed consent + randomized 
N= 5 209
Informed consent + randomized 
N= 5 400
Screening arm 
N= 5 305 
Control arm 
N= 5 304
Source population 
N= 79 142
Total randomized 
N= 10 609
21 764 abdominal obese expected 
based on prevalence 27.5%
74.1% of expected
48.7% of expected
STEP 1. 
Waist circumference 
STEP 1.  
Waist circumference 
Informed consent 
STEP 2. 
Informed consent 
Figure 2 Outcome screening procedure with the one-step and two-step screening methods.
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and IFG/impaired glucose tolerance was 3.3% and 5.7%,
respectively. In the Dutch Hoorn screening study, 11,679
individuals were invited to participate, of whom 7736
completed the SRQ [33]. Of the 7736, 2885 (37.3%) had a
high-risk profile and underwent a capillary glucose meas-
urement and 217 new cases of diabetes were detected.
Our study differs from those two studies with respect to
the study population (e.g. age, definition of “high risk”)
and the method used to verify diabetes, which may
explain the lower percentages of newly detected IFG
and diabetes in our study. In addition, the lower per-
centages may be related to improved efforts to detect
and treat unknown diabetes [34].The response rate following the initial invitation to
provide waist circumference measurements was only
26%, which could raise doubts about the success in
reaching the target group and the feasibility of the study.
However, this 26% is a proportion of all of the indivi-
duals contacted, not the actual study target group
(people with abdominal obesity who are at high risk).
The eventual proportion of anticipated high-risk indivi-
duals who agreed to undergo randomization was 49%.
Other projects involving the mailing of questionnaires
also show that the response rate can vary markedly de-
pending on the individual and the age group contacted.
This makes it difficult to predict response rates. The re-
sponse rate in a cluster-RCT of screening for delays in
Table 2 Characteristic of the control arm and the screening arm, and univariate and multivariate odds ratios and 95%
confidence intervals for determinants of attending screening
Control arm
n=5304
Screening arm
n=5305
P-value* Screening
attendees
Screening
non-attendees
Univariate OR
(95% CI)†
Multivariate OR
(95% CI)†
Age at randomization,
mean (range), yrs
56.7 (39.9 – 75.9) 56.6 (39.9 – 76.0) 0.299 57.0 54.4 1.03 (1.02-1.04),
p < 0.001
1.03 (1.02 – 1.04),
p < 0.001
Gender, male, % 43.9 43.7 0.778 43.4 44.9 0.94 (0.81-1.09),
p = 0.422
Marital status, married, % 74.4 73.6 0.379 75.4 64.5 1.69 (1.44-1.97),
p < 0.001
1.57 (1.33 – 1.83),
p < 0.001
Highest education
completed, %
Primary 9.5 9.6 0.917 9.2 11.2 0.89 (0.68-1.16),
p = 0.400
Lower secondary 40.8 39.9 40.3 38.2 1.14 (0.95-1.37),
p = 0.169
Upper secondary 24.2 24.8 25.3 23.1 1.18 (0.96-1.45),
p = 0.126
Tertiary 24.4 24.6 24.3 26.3 Reference
Smoking status,
current smoker, %
18.7 19.8 0.389 17.6 31.1 0.47 (0.40-0.56),
p < 0.001
0.52 (0.44 – 0.62),
p < 0.001
Waist circumference,
mean, cm
96.2 96.6 0.214 96.6 96.6 1.00 (0.99-1.01),
p = 0.377
Females 80–87, % 25.3 25.3 0.266 24.6 28.7
> = 88, % 74.7 74.7 75.4 71.3
Males 94–101, % 46.4 46.5 0.282 47.2 43.0
> = 102, % 53.5 53.5 52.6 57.0
Diabetes family history, % 27.2 26.4 0.350 26.5 25.8 1.04 (0.88-1.23),
p = 0.674
Country of birth, %
Netherlands 91.4 91.1 0.583 91.5 88.9 1.34 (1.05-1.70),
p = 0.017
1.20 (0.94-1.54),
p = 0.138
Other 8.6 8.9 8.5 11.1
Western country{ 4.0 4.0 4.1 3.5
Non-western country 4.6 4.9 4.4 7.5
Screening outcome
Attendance rate, n, (%) – 4457 (84.0)
Impaired fasting glucose, n (%) – 170 (3.8)
Diabetes, n (%) – 81 (1.8)
SCORE†>=5%, – 518 (11.6)
* Chi-square test for comparison of proportions and unpaired t-test for comparison of continuous variables between responders and non-responders.
† OR, odds ratio; CI, confidence interval; SCORE, Systematic COronary Risk Evaluation.
{ European countries (excluding Turkey), North America, Oceania, Indonesia or Japan.
Klijs et al. BMC Public Health 2012, 12:671 Page 8 of 11
http://www.biomedcentral.com/1471-2458/12/671language development conducted among 10,000 parents
of three-year-old children was 75% [35]. When invitations
to a trial of screening for prostate cancer were sent to
40,000 men, the response rate was 40% [36]. Sending out
general questionnaires through local health authorities for
a lung cancer screening project typically produced re-
sponse rates of around 32% [37]. Our observation of 49%
of the target high-risk population being randomized falls
within these previously reported rates.Limitations
As aforementioned, only 49% of the expected obese
population consented to participate. In the course of the
trial, efforts should be undertaken to further improve
participation rates, for instance, by sending reminders.
The study materials were written in easily understand-
able Dutch (targeted at level B1, advanced low, of the
Common European Framework of Reference for Lan-
guages [38]), to ensure that the study information was
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Figure 3 The distributions of the impaired fasting glucose and diabetes rates across males and females according to their
waist circumference.
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tainment and to reach the immigrant population. Adver-
tisements were placed in local newspapers in the two
study towns around the time that the letters were being
sent out. However, the participation rates among indivi-
duals with a low social status or from non-Dutch origin
were low and could probably also be improved by adapt-
ing the language to a lower level or by translation to
meet the specific requirements of these groups. The in-
volvement of people from local immigrant populations
in the recruitment process may prove to be effective.
In our study, we chose to use waist circumference as
the first-step screening tool rather than a questionnaire.
We did collect information using the nine questions of
the Dutch-validated SRQ, which was used as first screen-
ing step in the Hoorn Study [32] and the ADDITION
Netherlands study [31], but we did not use this infor-
mation. Several other risk questionnaires have been
developed to identify individuals with increased risk
of developing type 2 diabetes, of which the FINDRISC
tool was found to be the best available for use inclinical practice [39]. However, this tool has not yet
been validated in a Dutch population. Chamnan and col-
leagues recently calculated that using anthropometric
measures (BMI ≥25 kg/m2 or waist circumference >94 cm
in men and >80 cm in women) showed slightly higher
sensitivity and discriminatory ability compared with invit-
ing individuals based on the FINDRISC cut off or the
Cambridge risk score [40].
Conclusions
Self-reported home-assessed waist circumference proved
to be a feasible method for detecting persons at high risk
of hyperglycemia, but further work is necessary to in-
crease the uptake of this anthropometric measure as a
first-step screening tool. Continuation of this large-scale
RCT is warranted to establish whether diabetes screening
leads to a significant reduction in cardiovascular morbidity
and mortality. The results will contribute to the evidence
for or against the provision of screening for type 2 dia-
betes, and to the development of a strategy for the identi-
fication and selection of the population at risk.
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